1 |
Von Minckwitz G, Untch M, Blohmer JU, et al (2012). Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol, 30, 1-10.
DOI
|
2 |
Schott AF, Hayes DF (2012). Defining the benefits of neoadjuvant chemotherapy for breast cancer. J Clin Oncol, 30, 1747-9.
DOI
|
3 |
Smith IC, Heys SD, Hutcheon AW, et al (2002). Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol, 20, 1456-66.
DOI
ScienceOn
|
4 |
Voborilova J, Nemcova-Furstova V, Neubauerova J, et al (2011). Cell death induced by novel fluorinated taxanes in drug-sensitive and drug-resistant cancer cells. Invest New Drugs, 29, 411-23.
DOI
|
5 |
Chuthapisith S, Eremin JM, El-Sheemy M, Eremin O (2006). Neoadjuvant chemotherapy in women with large and locally advanced breast cancer: chemoresistance and prediction of response to drug therapy. Surgeon, 4, 211-9.
DOI
ScienceOn
|
6 |
Bourgarel-Rey V, Vallee S, Rimet O, et al (2001). Involvement of nuclear factor b in c-myc induction by tubulin polymerization inhibitors. Mol Pharmacol, 59, 1165-70.
|
7 |
Chang JC, Hilsenbeck SG (2004). Prognostic and predictive markers. In: Harris JR et al, (eds) Diseases of The Breast. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, pp.675-96.
|
8 |
Chen ZS, Tiwari AK (2011). Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J, 278, 3226-45.
DOI
|
9 |
Fan Y, Dutta J, Gupta N, Fan G, Gelinas C (2008). Regulation of programmed cell death by NF-kappaB and its role in tumorigenesis and therapy. Adv Exp Med Biol, 615, 223-50.
DOI
|
10 |
Ghavami S, Hashemi M, Ande SR, et al (2009). Apoptosis and cancer: mutations within caspase genes. J Med Genet, 46, 497-510.
DOI
ScienceOn
|
11 |
Godwin P, Baird AM, Heavey S, Barr MP, Gately K (2013), Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Front Oncol, 3, 1-10.
|
12 |
Gonzalez-Angulo AM, McGuire SE, Buchholz TA, et al (2005). Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol, 23, 7098-104.
DOI
|
13 |
IARC (2008). GLOBOCAN 2008, Section of Cancer Information.
|
14 |
Jones RL, Rojo F, A'Hern R, et al (2011). Nuclear NF-kappa B/p65 expression and response to neoadjuvant chemotherapy in breast cancer. J Clin Path, 64, 130-5.
DOI
|
15 |
O'Gorman DM, Cotter TG (2011). Molecular signals in antiapoptotic survival pathways. Leukemia, 15, 21-34.
|
16 |
Basseres DS, Baldwin AS (2006). Nuclear factor- and inhibitor of kinase pathways in oncogenic initiation and progression. Oncogene, 25, 5817-30.
|
17 |
Barre B, Coqueret O, Perkins ND (2010). Regulation of activity and function of the p52 NF- subunit following DNA damage. Cell Cycle, 9, 4795-804.
DOI
|